Neurocrine Biosciences Inc (1NBIX)

Currency in EUR
130.90
+0.25(+0.19%)
Closed·

1NBIX Financial Summary

Key Ratios

P/E Ratio36.17
Price/Book4.58
Debt / Equity15.97%
Return on Equity14.96%
Dividend Yield0.00%
EBITDA610.10M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of USD (except for per share items)

Earnings

Latest Release
Oct 28, 2025
EPS / Forecast
2.04 / --
Revenue / Forecast
794.90M / --
EPS Revisions
Last 90 days

FAQ

What were Neurocrine Biosciences Inc's earnings for the latest quarter?

The Neurocrine Biosciences Inc EPS (TTM) is 4.19. Neurocrine Biosciences Inc reported sales of 794.90, net income of 209.50, and EPS of 2.04 for the latest quarter.

What was Neurocrine Biosciences Inc's net income for the latest quarter?

Neurocrine Biosciences Inc's net income for the latest quarter was 209.50.

How did Neurocrine Biosciences Inc's performance compare year-over-year in the latest quarter?

The company's revenue moved from 687.50 in the previous quarter to 794.90 in the latest quarter, and net income moved from 107.50 to 209.50 compared to the previous quarter.

What is Neurocrine Biosciences Inc's net profit margin on a TTM basis?

Neurocrine Biosciences Inc's trailing twelve months (TTM) net profit margin is 14.49%.

How does Neurocrine Biosciences Inc's debt to equity ratio compare to industry standards?

Neurocrine Biosciences Inc's total debt-to-equity ratio is 15.97%.

What is Neurocrine Biosciences Inc's return on investment on a TTM basis?

Neurocrine Biosciences Inc's trailing twelve months (TTM) return on investment (ROI) is 14.96%.

Did Neurocrine Biosciences Inc gain or lose cash last quarter?

In the latest quarter, Neurocrine Biosciences Inc's net change in cash was 76.20 million.

What were Neurocrine Biosciences Inc's total assets and liabilities in the latest quarter?

As of the latest quarter, Neurocrine Biosciences Inc reported total assets of 4,265.70 million and total liabilities of 638.00 million.

How has Neurocrine Biosciences Inc's total revenue grown this year?

Neurocrine Biosciences Inc's total revenue was 687.50 in the previous quarter and 794.90 in the latest quarter.

What is Neurocrine Biosciences Inc's gross margin on a TTM basis?

Neurocrine Biosciences Inc's trailing twelve months (TTM) gross margin is 63.21%.

What was Neurocrine Biosciences Inc's revenue per share for the latest quarter?

Neurocrine Biosciences Inc's revenue per share for the latest quarter was 51.23.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.